Edition:
United Kingdom

Citius Pharmaceuticals Inc (CTXR.OQ)

CTXR.OQ on NASDAQ Stock Exchange Capital Market

2.74USD
5:50pm BST
Change (% chg)

$-0.14 (-4.86%)
Prev Close
$2.88
Open
$2.97
Day's High
$2.97
Day's Low
$2.69
Volume
5,828
Avg. Vol
8,303
52-wk High
$5.46
52-wk Low
$0.34

Chart for

About

Citius Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of critical care products targeting medical needs with a focus on anti-infective products, adjunctive cancer care, and prescription products. Its product candidates include Mino-Lok and Hydrocortiso... (more)

Overall

Beta: --
Market Cap(Mil.): $28.73
Shares Outstanding(Mil.): 9.98
Dividend: --
Yield (%): --

Financials

  CTXR.OQ Industry Sector
P/E (TTM): -- 31.01 33.60
EPS (TTM): -1.86 -- --
ROI: -55.85 13.60 13.19
ROE: -55.85 15.26 15.00

BRIEF-Citius Pharmaceuticals To Sell Up To 1.4 Mln Shares Of Co's Common Stock

* CITIUS PHARMACEUTICALS - TO SELL OR OTHER DISPOSITION FROM TIME TO TIME OF UP TO 1.4 MILLION SHARES OF CO'S COMMON STOCK Source : https://bit.ly/2JdehV7 Further company coverage: (Reuters.Briefs@thomsonreuters.com)

20 Apr 2018

BRIEF-Citius Announces $2 Mln Registered Direct Offering Priced At-The-Market

* CITIUS ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET Source text for Eikon: Further company coverage:

29 Mar 2018

BRIEF-Citius Reports Progress In Hemorroid Treatment Program

* CITIUS PHARMACEUTICALS - SELECTING HIGHER POTENCY CORTICOSTEROID IN ITS STEROID/ANESTHETIC TOPICAL FORMULATION PROGRAM FOR TREATMENT OF HEMORRHOIDS

06 Mar 2018

BRIEF-Citius Announces $6 Mln Registered Direct Offering Priced At-The-Market

* CITIUS ANNOUNCES $6 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

18 Dec 2017

BRIEF-Citius Pharmaceuticals Says On Nov 27, Board Appointed Jaime Bartushak As CFO And Principal Financial Officer Of Co

* CITIUS PHARMACEUTICALS INC - ‍ON NOV 27, , BOARD APPOINTED JAIME BARTUSHAK AS CFO AND PRINCIPAL FINANCIAL OFFICER OF COMPANY, EFFECTIVE NOV. 27, 2017​ Source text: (http://bit.ly/2iwTNyZ) Further company coverage:

01 Dec 2017

BRIEF-Citius Pharmaceuticals files for mixed shelf offering of up to $50 mln - SEC filing‍​

* Citius Pharmaceuticals Inc - files for mixed shelf offering of up to $50 million - SEC filing‍​ Source text: (http://bit.ly/2zKcjdY) Further company coverage:

09 Nov 2017

BRIEF-Citius pharmaceuticals receives "fast track" designation by FDA for mino-lok™ investigational trial

* Citius Pharmaceuticals, Inc. Receives "fast track" designation by FDA for mino-lok™ investigational trial Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

31 Oct 2017

Earnings vs. Estimates